Skip to main content
Publications
Arana A , Allen S, Burkowitz J, Fantoni V, Ghatnekar O, Rico MT, Vanhaverbeke N, Wentworth CE, Brosa M, Arellano FM. Infliximab paediatric Crohn's disease educational plan: a European, cross-sectional, multicentre evaluation . Drug Saf. 2010 Jun;33(6):489-501.
Hoyo C, Schildkraut JM, Murphy SK, Chow WH, Vaughan TL, Risch H, Marks JR, Jirtle RL, Calingaert B , Mayne S, Fraumeni, Jr. J, Gammon MD. IGF2R polymorphisms and risk of esophageal and gastric adenocarcinomas . Int J Cancer. 2009 Dec 1;125(11):2673-8.
Mangel AW, Fehnel SE , Earnshaw SR , Mangel TP. Pathway for the development of drugs to treat irritable bowel syndrome: from molecule identification through approval.. In: Driggers JD, Pellegrino CA, editors. Irritable bowel syndrome . Huntington: NY. Nova Science Publishers, Inc; 2009.
Guh S, Chen XB, Poulos C , Qi Z, Cao JW, von Seidlein L, Chen JC, Wang XY, Xing ZC, Nyamete A, Clemens J, Whittington D. Comparison of cost-of-illness with willingness-to-pay estimates to avoid shigellosis: evidence from China . Health Policy Plan. 2008 Mar 1;23(2):125-36.
Kim D, Canh DG, Poulos C , Thoa LTK, Cook J, Hoa NT, Nyamete A, Thuy DTD, Deen J, Clemens J, Thiem VD, Anh DD, Whittington D. Private demand for cholera vaccines in Hue,Vietnam . Value Health. 2008 Jan 1;11(1):119-28.